Holen Sie sich die Stockscreener-App
34.94
15.16%
4.60
Handel nachbörslich:
35.50
0.56
+1.60%
Schlusskurs vom Vortag:
$30.34
Offen:
$30.37
24-Stunden-Volumen:
1.90M
Relative Volume:
1.90
Marktkapitalisierung:
$1.91B
Einnahmen:
$199.89M
Nettoeinkommen (Verlust:
$52.48M
KGV:
41.11
EPS:
0.85
Netto-Cashflow:
$61.15M
1W Leistung:
+27.94%
1M Leistung:
+48.93%
6M Leistung:
+362.17%
1J Leistung:
+173.82%
1-Tages-Spanne:
$29.62
$35.08
1-Wochen-Bereich:
$27.15
$35.08
52-Wochen-Spanne:
$5.35
$35.08
Stoke Therapeutics Inc Stock (STOK) Company Profile
Firmenname
Stoke Therapeutics Inc
Sektor
Branche
Telefon
781-430-8200
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Vergleichen Sie STOK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
34.94 | 1.66B | 199.89M | 52.48M | 61.15M | 0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-18 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-03-26 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-07-25 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-24 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Eingeleitet | Jefferies | Buy |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-11-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Eingeleitet | UBS | Neutral |
| 2021-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-12-11 | Bestätigt | Needham | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-29 | Eingeleitet | Needham | Buy |
| 2019-12-18 | Eingeleitet | Wedbush | Outperform |
| 2019-11-12 | Eingeleitet | BTIG Research | Buy |
| 2019-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Credit Suisse | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Stoke Therapeutics stock price target raised to $39 by BTIG on positive data - Investing.com India
Is a relief rally coming for Stoke Therapeutics Inc. holders2025 Key Lessons & Free Verified High Yield Trade Plans - newser.com
Can Stoke Therapeutics Inc. rally from current levelsShare Buyback & Free Weekly Watchlist of Top Performers - newser.com
Stoke Therapeutics Hits New 52-Week High at $32.40, Up 104.84% - Markets Mojo
Edward Md Kaye Sells 25,000 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $35.00 at Needham & Company LLC - MarketBeat
Why Stoke Therapeutics (STOK) Is Up 18.1% After Positive Three-Year Data for Dravet Syndrome Therapy - Sahm
Stoke therapeutics director Kaye sells $750,000 in shares By Investing.com - Investing.com South Africa
Stoke therapeutics director Kaye sells $750,000 in shares - Investing.com
Biogen and Stoke add to zorevunersen data package in Dravet syndrome - The Pharma Letter
Needham raises Stoke Therapeutics stock price target to $35 on positive trial data - Investing.com Canada
Biogen, Stoke Therapeutics Present Positive Long-Term Data for Zorevunersen in Dravet Syndrome - MarketScreener
What is Leerink Partnrs' Estimate for STOK FY2027 Earnings? - MarketBeat
Needham Maintains Stoke Therapeutics (STOK) Buy Recommendation - Nasdaq
Needham Raises Stoke Therapeutics (STOK) Price Target by 59.09% to $35 | STOK Stock News - GuruFocus
Stoke Therapeutics, Inc. (STOK) Investor Outlook: Analyzing the High Revenue Growth and Strategic Partnerships in Biotechnology - DirectorsTalk Interviews
Will Stoke Therapeutics Inc. price bounce be sustainableJuly 2025 Catalysts & Smart Swing Trading Alerts - newser.com
How to integrate Stoke Therapeutics Inc. into portfolio analysis tools - newser.com
Using data tools to time your Stoke Therapeutics Inc. exitJuly 2025 Decliners & AI Optimized Trading Strategy Guides - newser.com
Biogen And Stoke Therapeutics Present Promising Long-Term Data For Zorevunersen In Dravet Syndrome - Nasdaq
Why Stoke Therapeutics (STOK) Is Up 20.5% After Zorevunersen Data Shows Sustained Benefits in Dravet Syndrome - Yahoo
Biogen's (BIIB) Zorevunersen Shows Promise in Treating Dravet Sy - GuruFocus
Biogen and Stoke Therapeutics Announce Positive Long-Term Results of Zorevunersen in Dravet Syndrome at Child Neurology Society Annual Meeting - Quiver Quantitative
Biogen and Stoke Therapeutics Present New Data at the 54th - GlobeNewswire
Stoke Therapeutics, Inc. and Biogen Inc. Present New Data at the 54th Child Neurology Society Annual Meeting That Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome - MarketScreener
Stoke Therapeutics Hits Day High with 11.68% Surge in Stock Price - Markets Mojo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Held Back By Insufficient Growth Even After Shares Climb 39% - simplywall.st
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 39% But Its Business Still Trails The Industry - 富途牛牛
Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains? - Yahoo Finance
Detecting price anomalies in Stoke Therapeutics Inc. with AIRate Cut & Fast Gain Swing Trade Alerts - newser.com
What the charts say about Stoke Therapeutics Inc. todayGlobal Markets & Real-Time Stock Entry Alerts - newser.com
Signal strength of Stoke Therapeutics Inc. stock in tech scannersEarnings Risk Summary & Reliable Trade Execution Plans - newser.com
Stoke Therapeutics (NASDAQ:STOK) Given "Sell (D+)" Rating at Weiss Ratings - MarketBeat
Will Stoke Therapeutics Inc. stock gain from lower inflation2025 Institutional Moves & Real-Time Volume Analysis - newser.com
Stoke Therapeutics’ Stock Climbs: What’s Next? - timothysykes.com
Stoke Therapeutics (NASDAQ:STOK) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Stoke Therapeutics stock hits 52-week high at 28.03 USD By Investing.com - Investing.com South Africa
Stoke Therapeutics stock hits 52-week high at 28.03 USD - Investing.com
Stoke Therapeutics Hits New 52-Week High at $28.00, Up 80% - Markets Mojo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 10,000 Shares - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Sells 42,461 Shares - MarketBeat
Stoke Therapeutics Appoints Ian F. Smith as CEO - The Globe and Mail
Stoke Therapeutics Hits New 52-Week High of $25.61, Up 71.66% - Markets Mojo
Stoke Therapeutics appoints Ian Smith as permanent CEO By Investing.com - Investing.com Canada
Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025 - FinancialContent
Stoke Therapeutics (NASDAQ:STOK) Sets New 12-Month HighStill a Buy? - MarketBeat
Stoke Therapeutics, Inc. Appoints Ian F. Smith as Chief Executive Officer - MarketScreener
Stoke Therapeutics Inc.’s volatility index tracking explainedMarket Activity Recap & Precise Entry and Exit Recommendations - newser.com
Stoke Therapeutics (STOK) Appoints Ian F. Smith as CEO - GuruFocus
Stoke Therapeutics names Ian F. Smith as permanent CEO and principal executive - Investing.com
Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):